serine has been researched along with Ovarian Neoplasms in 32 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression." | 7.75 | Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009) |
| "Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, including epithelial ovarian cancer." | 4.12 | Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. ( Agami, R; Amant, F; Annibali, D; Baiden-Amissah, REM; Berardi, E; Berkers, CR; Carmeliet, P; Davidson, B; De Wispelaere, W; Duarte, JAG; Eelen, G; Fendt, SM; Horlings, HM; Körner, PR; Lambrechts, D; Moens, S; Planque, M; Rizzotto, L; Rossi, M; Sonke, GS; Swinnen, JV; Talebi, A; Van Nyen, T; van Wagensveld, L; Zaal, EA, 2022) |
| " The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression." | 3.75 | Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009) |
| "The gene expression in ovarian cancer cells was detected by Western blot and quantitative real-time PCR." | 1.91 | PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathway. ( Chen, K; Lu, W; Shen, Z; Shi, Y; Tang, S; Wang, F; Wang, S; Wu, Y; Xia, D; Yuan, X; Zheng, F; Zhong, J, 2023) |
| "The study was performed on ovarian cancer cell line (OvBH-1), colon adenocarcinoma metastasis to ovary (SW626) and on cells isolated from ascitic fluids from patients with ovarian cancer: with (p53+) or without (p53-) p53 nuclear protein accumulation." | 1.48 | The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study. ( Bar, JK; Kamińska, I, 2018) |
| "Irinotecan has also displayed efficacy in clinical trials of NSCLC." | 1.42 | Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. ( Gjerset, RA; Zhao, M, 2015) |
| "Less than 50% of ovarian cancers respond to paclitaxel." | 1.37 | The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. ( Ahmed, AA; Bast, RC; Claret, FX; He, G; Hung, MC; Le, XF; Mao, W; Siddik, ZH; Xia, W, 2011) |
| " Pharmacokinetic analysis showed 9ING41 to have a bioavailability of 4." | 1.37 | Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. ( Burdette, JE; Gaisin, AM; Gaisina, IN; Gallier, F; Hilliard, TS; Muehlbauer, AG, 2011) |
| "Here, we show that breast-ovarian cancer susceptibility 1 (BRCA1) interacts directly with ATR-interacting protein (ATRIP), an obligate partner of ATR." | 1.34 | Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function. ( Halazonetis, TD; Snyder, A; Venere, M; Zgheib, O, 2007) |
| "Two human ovarian cancer cell lines SKOV3 and ES-2 were analysed for the expression of GSK-3beta and phosphorylated GSK-3beta (pGSK-3beta) by Western blot analysis." | 1.33 | [Glycogen synthase kinase-3beta (GSK-3beta) promotes proliferation of ovarian cancer cells in vitro]. ( Cao, Q; Feng, YJ, 2006) |
| "Thus, treatment of ovarian cancer with paclitaxel might be less effective in the setting of postoperative estrogen replacement therapy." | 1.32 | Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. ( Arimoto-Ishida, E; Kimura, A; Mabuchi, S; Murata, Y; Nishio, Y; Ohmichi, M; Tasaka, K; Yada-Hashimoto, N, 2004) |
| "In this study we found that in ovarian cancer cells, CHK2 kinase is activated by irofulven while CHK1 kinase is not activated even when treated at higher concentrations of the drug." | 1.32 | ATM-dependent CHK2 activation induced by anticancer agent, irofulven. ( Burks, J; Cunningham, C; Mikell, C; Reed, E; Van Laar, ES; Wang, J; Wang, W; Wang, Y; Waters, SJ; Wiltshire, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 10 (31.25) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Eroglu, EC | 1 |
| Kucukgoz Gulec, U | 1 |
| Vardar, MA | 1 |
| Paydas, S | 1 |
| Van Nyen, T | 1 |
| Planque, M | 1 |
| van Wagensveld, L | 1 |
| Duarte, JAG | 1 |
| Zaal, EA | 1 |
| Talebi, A | 1 |
| Rossi, M | 1 |
| Körner, PR | 1 |
| Rizzotto, L | 1 |
| Moens, S | 1 |
| De Wispelaere, W | 1 |
| Baiden-Amissah, REM | 1 |
| Sonke, GS | 1 |
| Horlings, HM | 1 |
| Eelen, G | 1 |
| Berardi, E | 1 |
| Swinnen, JV | 1 |
| Berkers, CR | 1 |
| Carmeliet, P | 1 |
| Lambrechts, D | 1 |
| Davidson, B | 1 |
| Agami, R | 1 |
| Fendt, SM | 1 |
| Annibali, D | 1 |
| Amant, F | 1 |
| Zheng, F | 1 |
| Zhong, J | 1 |
| Chen, K | 1 |
| Shi, Y | 1 |
| Wang, F | 1 |
| Wang, S | 1 |
| Tang, S | 2 |
| Yuan, X | 1 |
| Shen, Z | 1 |
| Xia, D | 1 |
| Wu, Y | 1 |
| Lu, W | 1 |
| Lancien, M | 1 |
| Gueno, L | 1 |
| Salle, S | 1 |
| Merieau, E | 1 |
| Beriou, G | 1 |
| Nguyen, TH | 1 |
| Abidi, A | 1 |
| Dilek, N | 1 |
| Solomon, P | 1 |
| Poschmann, J | 1 |
| Michielin, O | 1 |
| Vuillefroy de Silly, R | 1 |
| Vanhove, B | 1 |
| Louvet, C | 1 |
| Tsai, CL | 1 |
| Jung, SM | 1 |
| Chi, LM | 1 |
| Tsai, CN | 1 |
| Lin, CY | 1 |
| Chao, A | 1 |
| Lee, YS | 1 |
| Kamińska, I | 1 |
| Bar, JK | 2 |
| Bar, J | 1 |
| Grelewski, P | 1 |
| Deszcz, I | 1 |
| Noga, L | 2 |
| Hirnle, L | 1 |
| Lis-Nawara, A | 1 |
| Ryu, KJ | 1 |
| Park, SM | 1 |
| Park, SH | 1 |
| Kim, IK | 1 |
| Han, H | 1 |
| Kim, HJ | 1 |
| Kim, SH | 1 |
| Hong, KS | 1 |
| Kim, H | 1 |
| Kim, M | 1 |
| Yoon, SJ | 1 |
| Asaithambi, K | 1 |
| Lee, KH | 1 |
| Park, JY | 1 |
| Hah, YS | 1 |
| Cho, HJ | 1 |
| Yook, JI | 1 |
| Yang, JW | 1 |
| Ko, GH | 1 |
| Lee, G | 1 |
| Kang, YJ | 1 |
| Hwangbo, C | 1 |
| Kim, KD | 1 |
| Park, YJ | 1 |
| Yoo, J | 1 |
| Zaoui, K | 1 |
| Boudhraa, Z | 1 |
| Khalifé, P | 1 |
| Carmona, E | 1 |
| Provencher, D | 1 |
| Mes-Masson, AM | 1 |
| Wang, Y | 5 |
| Xiang, J | 1 |
| Ji, F | 1 |
| Deng, Y | 1 |
| Tang, C | 1 |
| Yang, S | 1 |
| Xi, Q | 1 |
| Liu, R | 1 |
| Di, W | 1 |
| Zhao, M | 1 |
| Gjerset, RA | 1 |
| Xu, D | 1 |
| Song, R | 1 |
| Wang, G | 1 |
| Jeyabal, PV | 1 |
| Weiskoff, AM | 1 |
| Ding, K | 1 |
| Shi, ZZ | 1 |
| Bhatt, M | 1 |
| Ivan, C | 1 |
| Xie, X | 1 |
| Siddik, ZH | 2 |
| Radu, M | 1 |
| Soprano, DR | 2 |
| Soprano, KJ | 2 |
| Cheng, C | 1 |
| Ji, Y | 1 |
| Zhao, Y | 1 |
| Zou, L | 1 |
| Shen, A | 1 |
| Słomska, I | 1 |
| Rabczyńki, J | 1 |
| Gryboś, M | 1 |
| Le, XF | 1 |
| Mao, W | 1 |
| He, G | 1 |
| Claret, FX | 1 |
| Xia, W | 1 |
| Ahmed, AA | 1 |
| Hung, MC | 1 |
| Bast, RC | 1 |
| Hilliard, TS | 1 |
| Gaisina, IN | 1 |
| Muehlbauer, AG | 1 |
| Gaisin, AM | 1 |
| Gallier, F | 1 |
| Burdette, JE | 1 |
| Mabuchi, S | 1 |
| Ohmichi, M | 2 |
| Kimura, A | 1 |
| Nishio, Y | 2 |
| Arimoto-Ishida, E | 1 |
| Yada-Hashimoto, N | 1 |
| Tasaka, K | 2 |
| Murata, Y | 2 |
| Wang, J | 2 |
| Wiltshire, T | 1 |
| Mikell, C | 1 |
| Burks, J | 1 |
| Cunningham, C | 1 |
| Van Laar, ES | 1 |
| Waters, SJ | 1 |
| Reed, E | 1 |
| Wang, W | 1 |
| Karppinen, SM | 1 |
| Heikkinen, K | 1 |
| Rapakko, K | 1 |
| Winqvist, R | 1 |
| Ramírez, CJ | 1 |
| Haberbusch, JM | 1 |
| Fraser, M | 1 |
| Chan, SL | 1 |
| Chan, SS | 1 |
| Fiscus, RR | 1 |
| Tsang, BK | 1 |
| Cao, Q | 1 |
| Feng, YJ | 1 |
| Venere, M | 1 |
| Snyder, A | 1 |
| Zgheib, O | 1 |
| Halazonetis, TD | 1 |
| Cai, G | 1 |
| Xin, X | 1 |
| Ke, Z | 1 |
| Luo, J | 1 |
| Kim, TJ | 1 |
| Ravoori, M | 1 |
| Landen, CN | 1 |
| Kamat, AA | 1 |
| Han, LY | 1 |
| Lu, C | 1 |
| Lin, YG | 1 |
| Merritt, WM | 1 |
| Jennings, N | 1 |
| Spannuth, WA | 1 |
| Langley, R | 1 |
| Gershenson, DM | 1 |
| Coleman, RL | 1 |
| Kundra, V | 1 |
| Sood, AK | 1 |
| Lappi, DA | 1 |
| Matsunami, R | 1 |
| Martineau, D | 1 |
| Baird, A | 1 |
| Plummer, SJ | 1 |
| Anton-Culver, H | 1 |
| Webster, L | 1 |
| Noble, B | 1 |
| Liao, S | 1 |
| Kennedy, A | 1 |
| Belinson, J | 1 |
| Casey, G | 1 |
| Tanyi, J | 1 |
| Páy, A | 1 |
| Rigó, J | 1 |
| Nagy, B | 1 |
| Papp, Z | 1 |
| Hayakawa, J | 1 |
| Kurachi, H | 1 |
| Kanda, Y | 1 |
| Hisamoto, K | 1 |
| Adachi, K | 1 |
| Kanzaki, T | 1 |
| Wolberg, WH | 1 |
32 other studies available for serine and Ovarian Neoplasms
| Article | Year |
|---|---|
GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor.
Topics: Benzoic Acid; Biomarkers; Creatinine; Female; Gas Chromatography-Mass Spectrometry; Glutathione; Gly | 2022 |
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local | 2022 |
PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathway.
Topics: Animals; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoric | 2023 |
Cystathionine-gamma-lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy.
Topics: Adoptive Transfer; Animals; CD8-Positive T-Lymphocytes; Cell Engineering; Cell Line, Tumor; Cell Pro | 2021 |
Glycogen synthase kinase-3 beta (GSK3β)-mediated phosphorylation of ETS1 promotes progression of ovarian carcinoma.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Female; Glycogen | 2021 |
The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell | 2018 |
Association between p53 protein phosphorylated at serine 20 expression and ovarian carcinoma stem cells phenotype: correlation with clinicopathological parameters of ovarian cancer.
Topics: AC133 Antigen; Biomarkers, Tumor; Female; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Phenotyp | 2019 |
p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation That Is Required for GSK3β-βTrCP-Induced Snail Degradation.
Topics: Animals; beta-Transducin Repeat-Containing Proteins; Cell Line, Tumor; Dyrk Kinases; Epithelial-Mese | 2019 |
Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Female; Gene Knockdown Techniques; H | 2019 |
Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.
Topics: Active Transport, Cell Nucleus; Adult; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cel | 2014 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2015 |
Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3β-inhibitor 2-PP1 positive feedback loop.
Topics: Adenosine Triphosphatases; Animals; Blotting, Western; Colorectal Neoplasms; Feedback, Physiological | 2016 |
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 2; Cisplatin; CRISPR-Cas S | 2017 |
S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin-Dependent Kinase I | 2008 |
Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.
Topics: Adult; Aged; Carcinoma in Situ; COP9 Signalosome Complex; Cyclin-Dependent Kinase 2; Cyclin-Dependen | 2009 |
Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Hu | 2009 |
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; CDC2 Protein Kinase; Cell Line, Tumor; Cell Pr | 2011 |
Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth.
Topics: Animals; Apoptosis; Biological Availability; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug S | 2011 |
Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Estrogens | 2004 |
ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell | 2004 |
Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
Topics: Alleles; Amino Acid Sequence; Breast Neoplasms; Cysteine; DNA Mutational Analysis; Female; Finland; | 2004 |
Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Dimerization; Down-Regulation; Female; Humans; JNK Mitogen-Activated Pr | 2005 |
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Topics: Adenoviridae; Apoptosis; Atrial Natriuretic Factor; bcl-2-Associated X Protein; Benzothiazoles; Casp | 2006 |
[Glycogen synthase kinase-3beta (GSK-3beta) promotes proliferation of ovarian cancer cells in vitro].
Topics: beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Female; Glycogen Synthase Kin | 2006 |
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Ataxia Telangiectasia Mutated Proteins; B | 2007 |
Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Glycogen S | 2007 |
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cel | 2007 |
Reducing the heterogeneity of chemically conjugated targeted toxins: homogeneous basic FGF-saporin.
Topics: 3T3 Cells; Animals; Base Sequence; Blotting, Western; Cysteine; Female; Fibroblast Growth Factor 2; | 1993 |
Detection of BRCA1 mutations by the protein truncation test.
Topics: Adult; Age of Onset; Base Sequence; BRCA1 Protein; Breast Neoplasms; Chromosome Mapping; Chromosomes | 1995 |
[Mutation analysis of the beta-catenin gene in epithelial carcinomas of the ovaries].
Topics: Adult; Age Factors; Aged; beta Catenin; Cadherins; Carcinoma; Cytoskeletal Proteins; DNA, Neoplasm; | 2000 |
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Topics: Adenocarcinoma, Papillary; Androstadienes; Antineoplastic Agents; bcl-Associated Death Protein; Carr | 2000 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |